Nephrology

Back to articles

Decreasing cardiovascular risk in chronic kidney disease: Cinacalcet disappoints

KEY POINT

In patients with chronic kidney disease and moderate-to-severe hyperparathyroidism who were undergoing hemodialysis, use of cinacalcet (Sensipar—Amgen) for up to 5 years did not significantly reduce the risk of death or major cardiovascular events as compared to placebo.

SOURCES

The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–94.

Perkovic V et al. Trials in kidney disease—time to EVOLVE [Editorial]. N Engl J Med. 2012;367:2541–2.